Prognostic Value of SII and SIRI in Obesity-Related Metabolic Complications
Recruiting · NCT07431593 · Observational (researchers observe without assigning treatment) · Lead sponsor: University of Rijeka
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
This observational study aims to evaluate the diagnostic and prognostic value of the systemic immune-inflammatory index (SII) and the systemic inflammation response index (SIRI) in individuals with overweight or obesity. The study will assess their association with obesity status, metabolic complications, lifestyle patterns, dietary indices, and established inflammatory biomarkers. Participants will undergo anthropometric assessment, laboratory testing, dietary evaluation, and follow-up for response to different obesity treatment modalities over 3 years. The study intends to determine whether SII and SIRI can serve as clinically useful predictors of metabolic risk and treatment outcomes of obesity.
Who can take part
Inclusion criteria
- Age ≥ 18 years
- BMI 25.0-29.9 kg/m² (overweight) or BMI ≥ 30 kg/m² (obesity)
- Ability to attend scheduled clinical visits
- Willingness to provide informed consent
Exclusion criteria
- Pregnancy or breastfeeding
- Use of immunosuppressive therapy
- Active infection
- Inflammatory disease
- Malignancy
- Acute illness affecting immune parameters
- Conditions interfering with study participation (as assessed by the investigator)
- Known hematologic disorders affecting leukocyte or platelet counts
- Chronic inflammatory diseases requiring systemic therapy
- Recent major surgery (within the last 3 months)
- Any condition that could confound the relationship between SII/SIRI and obesity-driven inflammation, such as immune disorders
Where it is running
1 location listed.
- General Hospital Varaždin - Varaždin, Croatia